FEDERAL · 2026-16727
Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
SEP 16, 2026Other rules
Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product. Issued by Health and Human Services Department, Food and Drug Administration.
What changes
Other rules
Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
Timeline
Published August 17, 2026
Takes effect September 16, 2026
Official text
Source: U.S. Federal Register (public domain) · View the official text ↗. The effective date comes from the official document; confirm on the source.